Detail

Basic Information Clinical Results Relationship Graph

Gene symbol	STAT3	Synonyms	ADMIO, ADMIO1, APRF, HIES	Type of gene	protein-coding
Chromosome	17	Map location	17q21.2	dbXrefs
Gene perturbation-related omics dataset	PerturbAtlas \| PertOrg
Description	signal transducer and activator of transcription 3

GTO ID	GTC1547
Trial ID	NCT02546661
Disease	Muscle Invasive Bladder Cancer
Altered gene	STAT3
Therapeutic/Target gene	Target gene
Therapy	ASO
Treatment	ISIS-STAT3rx\|AZD9150\|ISIS 481464\|IONIS-STAT3-2.5Rx
Phase	Phase1
Recruitment status	Active, Not Recruiting
Title	An Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in Patients With Muscle Invasive Bladder Cancer (MIBC) Who Have Progressed on Prior Treatment (BISCAY).
Year	2016
Country	Canada\|France\|Spain\|United Kingdom\|United States
Company sponsor	AstraZeneca
Other ID(s)	D2615C00001\|GU 118\|BISCAY\|2015-002228-25

Vector information

Vector	No vector was used

Cohort1: AZD4547

Cohort2: AZD4547_MEDI4736

Administration route	oral\|intravenous infusion
Dosage	AZD4547, twice daily\|MEDI4736, once every 4 weeks
Age	Adult, Older_Adult
References	PMID: 33941921

Cohort3: MEDI4736_Olaparib_selected

Administration route	intravenous infusion\|oral
Dosage	MEDI4736, once every 4 weeks\|Olaparib, twice daily
Age	Adult, Older_Adult
References	PMID: 33941921

Cohort4: MEDI4736_Olaparib_unselected

Administration route	intravenous infusion\|oral
Dosage	MEDI4736, once every 4 weeks\|Olaparib, twice daily
Age	Adult, Older_Adult
References	PMID: 33941921

Cohort5: MEDI4736_AZD1775

Administration route	intravenous infusion\|oral
Dosage	MEDI4736, once every 4 weeks\|AZD1775, approximate 12 hour intervals over 3 days (6 doses) on Days 1-3, 8-10, and 15-17 of 28 day cycles
Age	Adult, Older_Adult
References	PMID: 33941921

Cohort6: MEDI4736

Cohort7: MEDI4736_Vistusertib

Administration route	intravenous infusion\|oral
Dosage	MEDI4736, once every 4 weeks\|Vistusertib, twice per day on an intermittent schedule (2 days on, 5 days off)
Age	Adult, Older_Adult
References	PMID: 33941921

Cohort8: MEDI4736_AZD9150

Administration route	intravenous infusion
Dosage	MEDI4736, on Day 1 of each 28 day cycle, thereafter once every 4 weeks\|AZD9150, on Days -7, -5, and -3 of a one week lead-in period, thereafter weekly
Age	Adult, Older_Adult
References	PMID: 33941921

Cohort9: MEDI4736_Selumetinib

Overview of Knowledge Graph